Paul H. Moss
Distinguished in Chronic Lymphocytic Leukemia (CLL)

Paul H. Moss

Birmingham, ENG, GB 
Distinguished in Chronic Lymphocytic Leukemia (CLL)
Birmingham, ENG, GB 
OverviewLocationsClinical Research

Overview

Paul Moss practices in Birmingham, United Kingdom. Mr. Moss is rated as a Distinguished expert by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 219 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 29 articles in the study of Chronic Lymphocytic Leukemia (CLL).

Gender
Male

Locations

Birmingham, ENG, United Kingdom
Other Locations
Guildford, ENG GU27WG, United Kingdom
Edgbaston, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Subclinical Cytomegalovirus Reactivation in Patients With Newly Diagnosed or Relapsed ANCA-associated Vasculitis and Adverse Clinical Outcomes
Subclinical Cytomegalovirus Reactivation in Patients With Newly Diagnosed or Relapsed ANCA-associated Vasculitis and Adverse Clinical Outcomes
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2024
A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers
A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis
A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis
Enrollment Status: Terminated
Publish Date: August 31, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 2 Less Clinical Trials

219 Total Publications

Protective SARS-CoV-2-specific T cells take up residence.
Protective SARS-CoV-2-specific T cells take up residence.
Journal: Nature immunology
Published: February 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Moss's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile